Literature DB >> 17133084

Chemoprevention of colorectal neoplasia: advances and controversies (the COX-2 story).

Robert S Bresalier.   

Abstract

PURPOSE OF REVIEW: Colorectal cancer is prevalent, deadly and expensive to treat. Chemoprevention provides an opportunity to prevent colorectal cancer through prevention of precursor adenomas. RECENT
FINDINGS: Three prospective randomized trials demonstrate significant reductions in new sporadic adenoma formation in individuals taking COX-2 selective inhibitors compared to placebo, but with an associated increase in cardiovascular risk.
SUMMARY: Chemoprevention of colorectal adenomas with COX-2 selective nonsteroidal anti-inflammatory drugs is feasible, but these agents are unlikely to be used routinely for prevention of sporadic adenomas due to associated cardiovascular risk. Their use in other groups will depend on the answers to several questions regarding mechanisms of action and risk versus benefit.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17133084     DOI: 10.1097/MOG.0b013e328011c482

Source DB:  PubMed          Journal:  Curr Opin Gastroenterol        ISSN: 0267-1379            Impact factor:   3.287


  4 in total

1.  Interactive effects of fatty acid and butyrate-induced mitochondrial Ca²⁺ loading and apoptosis in colonocytes.

Authors:  Satya Kolar; Rola Barhoumi; Chris K Jones; Joshua Wesley; Joanne R Lupton; Yang-Yi Fan; Robert S Chapkin
Journal:  Cancer       Date:  2011-05-11       Impact factor: 6.860

2.  Association of stem-like cells in gender-specific chemoprevention against intestinal neoplasia in MIN mouse.

Authors:  Seema R Gandhi; Ashish K Tiwari; Dhananjay P Kunte; Mart Angelo De la Cruz; Yolanda Stypula; Tina Gibson; Jeffrey Brasky; Vadim Backman; Ramesh K Wali; Hemant K Roy
Journal:  Oncol Rep       Date:  2011-07-18       Impact factor: 3.906

3.  Perspectives on the treatment of colorectal carcinoma.

Authors:  Ren Zhao; Jing Li
Journal:  World J Gastrointest Oncol       Date:  2010-05-15

4.  Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid.

Authors:  Powel H Brown; Kotha Subbaramaiah; Amoi P Salmon; Rebecca Baker; Robert A Newman; Peiying Yang; Xi Kathy Zhou; Reid P Bissonnette; Andrew J Dannenberg; Louise R Howe
Journal:  Cancer Prev Res (Phila)       Date:  2008-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.